Rigel Pharmaceuticals, Inc. — 2023 Form 10-K
Business context and period. Annual report for the fiscal year ended December 31, 2023, filed March 5, 2024. Rigel is a commercial-stage biotechnology company selling TAVALISSE for chronic ITP and REZLIDHIA for IDH1-mutated relapsed or refractory AML, while developing additional therapies and relying on partners for certain programs and international sales.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Total revenue | $116.9 million | $120.2 million |
| Net product sales | $104.3 million | $76.7 million |
| Collaboration revenue | $11.5 million | $39.0 million |
| Government contract revenue | $1.1 million | $4.5 million |
| Operating loss | $20.5 million | $55.6 million |
| Net loss | $25.1 million | $58.6 million |
| Net loss per share | $0.14 | $0.34 |
| Cash and short-term investments, year-end | $56.9 million | $58.2 million |
| Net cash used in operating activities | $5.7 million | $73.8 million |
| Term-loan principal, year-end | $60.0 million | $40.0 million |
TAVALISSE net sales increased 24% to $93.7 million; REZLIDHIA net sales rose to $10.6 million from $0.9 million as commercialization began in December 2022. Product sales were reported net of $42.8 million in discounts and allowances. Cost of product sales was $7.1 million; the filing notes it was reduced by previously expensed, pre-approval inventory costs, so this figure should not be treated as a normalized product margin.
Revenue declined slightly despite product growth, primarily because 2022 included substantial collaboration milestones and license revenue, including Kissei’s Japan milestones and Lilly-related revenue. Research and development expense fell to $24.5 million from $60.3 million, mainly reflecting trial timing/completions and lower related costs. Selling, general and administrative expense decreased to $105.7 million from $112.5 million. Interest expense increased to $6.9 million from $3.7 million.
Year-end current assets were $99.3 million and current liabilities were $53.3 million. Total liabilities were $145.9 million, compared with total assets of $117.2 million; stockholders’ deficit was $28.6 million. The $60.0 million MidCap loan bears interest at one-month SOFR plus a 5.65% margin, subject to a 1.50% floor; its stated maturity is September 2026, with interest-only payments through October 2024. No principal payments were due within 12 months under the filing’s contractual-obligations discussion, although the debt schedule shows $7.5 million of principal payments for 2024.
Material developments, outlook and risks
- GAVRETO: In February 2024, after year-end, Rigel agreed to acquire US rights to GAVRETO for $15.0 million, with up to $102.5 million in additional regulatory and commercial milestones and tiered royalties of 10%–30%. Rigel expected to begin recognizing sales in the third quarter of 2024. The thyroid-cancer indication has accelerated approval and requires confirmatory evidence of clinical benefit.
- Liquidity outlook: Management said existing capital resources were expected to fund current and projected requirements for at least 12 months from the filing date. It also expects operating losses to continue in the next 12 months and warns that additional capital may be needed; future financing could dilute shareholders or impose restrictive terms.
- Partner and program commitments: Rigel’s MD Anderson collaboration involves $15.0 million of time-based payments over five years; the CONNECT collaboration involves up to $3.0 million over four years. Following its first opt-out notice under the Lilly agreement, Rigel remained responsible for up to $22.6 million of R552 development costs through April 1, 2024.
- Clinical updates: Rigel reported that a statistical-stratification error by a CRO affected the initial analysis of its FOCUS COVID-19 trial; a corrected analysis met the primary endpoint (4.8 versus 7.6 mean days on oxygen; p=0.0136). Despite that result, Rigel decided not to seek an EUA or supplemental approval. Separately, an NIH/NHLBI monitoring board recommended stopping enrollment in its ACTIV-4 fostamatinib arm, citing an extremely low likelihood of benefit on the primary or secondary outcomes; no safety concern was identified. Fostamatinib’s Phase 3 warm-AIHA study also failed its primary endpoint, and Rigel did not file for approval for that indication.
- Key risks: Commercial results depend heavily on TAVALISSE and REZLIDHIA uptake, reimbursement and pricing, and successful integration and commercialization of GAVRETO. TAVALISSE faces an ongoing patent-infringement dispute with Annora over its generic application; no trial date was set. Rigel also cites competition, clinical and regulatory uncertainty, reliance on third-party manufacturing and distribution, and exposure to variable-rate debt. The auditor identified product-sales allowances and discounts as a critical audit matter, citing judgment involved in estimates; the financial-statement opinion was unqualified.
Most important facts for investors to verify
- Whether TAVALISSE sales growth continues and how rebates, chargebacks and the $15.7 million year-end revenue-reserve/refund liability develop.
- REZLIDHIA sales trajectory, commercial adoption, royalty costs and any development or regulatory milestones payable to Forma.
- GAVRETO transaction closing and transition progress, first-sale timing, economics of royalties and milestones, and confirmatory requirements for its accelerated-approval indication.
- Cash burn, financing needs and compliance with MidCap’s minimum-cash and trailing-net-revenue covenants; reconcile the filing’s 2024 debt-payment disclosures.
- Outcome and timing of the Annora patent litigation, and any regulatory or commercial developments affecting generic entry for TAVALISSE.
- Further clinical evidence for R289 and REZLIDHIA expansion studies, as well as final data and implications from the stopped ACTIV-4 COVID-19 study arm.